ICER slightly softens its recommendation on Pfizer's ATTR-CM drug price
A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as Vyndamax and Vyndaqel, should …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
